Fludarabine induces pro-inflammatory activation of human monocytic cells through a MAPK/ERK pathway

International Immunopharmacology

Volumn 6, Issue 5, 2006, Pages 715-723

  Fernández Calotti, Paula ^a   Gamberale, Romina ^a   Costas, Mónica ^b   Sánchez Ávalos, Julio ^c   Geffner, Jorge ^a   Giordano, Mirta ^a  

^a INST DE INVEST HEMATOLOGICAS   (Argentina)

^b INSTITUTO DE INVESTIGACIONES MÉDICAS ALFREDO LANARI   (Argentina)

^c HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

Author keywords

AP 1; Fludarabine; MAPK ERK; Monocytes

Indexed keywords

ACETYLCYSTEINE; FLUDARABINE; I KAPPA B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1;

APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL STIMULATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; INFLAMMATION; INHIBITION KINETICS; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; B-LYMPHOCYTES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-8; MONOCYTES; TRANSCRIPTION FACTOR AP-1; U937 CELLS; VIDARABINE;

EID: 33645031243     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2005.08.027     Document Type: Article

References (51)

1. M.J. Keating, H. Kantarjian, M. Talpaz, J. Redman, and C. Koller Fludarabine: a new agent with major activity against chronic lymphocytic leukemia Blood 74 1989 19 25
2. G. Lenz, W. Hiddemann, and M. Dreyling The role of fludarabine in the treatment of follicular and mantle cell lymphoma Cancer 101 2004 883 893
3. C.S. Tam, M.M. Wolf, E.H. Januszewicz, H.M. Prince, D. Westerman, and J.F. Seymour Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies Cancer 100 2004 2181 2189
4. U. Platzbecker, G. Ehninger, N. Schmitz, and M. Bornhauser Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation in myeloid diseases Ann Hematol 82 2003 463 468
5. A. Bashey Immunosuppression with limited toxicity: the characteristics of nucleoside analogs and anti-lymphocyte antibodies used in non-myeloablative hematopoietic cell transplantation Cancer Treat Res 110 2002 39 49
6. D.A. Jacobsohn, R. Duerst, W. Tse, and M. Kletzel Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children Lancet 364 2004 156 162
7. P. Huang, S. Chubb, and W. Plunkett Termination of DNA synthesis by 9-beta-d-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity J Biol Chem 265 1990 16617 16625
8. C.M. Galmarini, J.R. Mackey, and C. Dumontet Nucleoside analogues: mechanisms of drug resistance and reversal strategies Leukemia 15 2001 875 890
9. A. Klopfer, A. Hasenjager, C. Belka, K. Schulze-Osthoff, B. Dorken, and P.T. Daniel Adenine deoxynucleotides fludarabine and cladribine induce apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway Oncogene 23 2004 9408 9418
10. T. Yamauchi, B.J. Nowak, M.J. Keating, and W. Plunkett DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxy cyclophosphamide is inhibited by fludarabine and clofarabine Clin Cancer Res 7 2001 3580 3589
11. V.A. Rao, and W. Plunkett Activation of a p53-mediated apoptotic pathway in quiescent lymphocytes after the inhibition of DNA repair by fludarabine Clin Cancer Res 9 2003 3204 3212
12. D. Genini, I. Budihardjo, W. Plunkett, X. Wang, C.J. Carrera, and H.B. Cottam Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway J Biol Chem 275 2000 29 34
13. J.A. Vrana, Z. Wang, A.S. Rao, L. Tang, J.H. Chen, and L.B. Kramer Induction of apoptosis and differentiation by fludarabine in human leukemia cells (U937): interactions with the macrocyclic lactone bryostatin 1 Leukemia 13 1999 1046 1055
14. G. Eissner, G. Multhoff, A. Gerbitz, S. Kirchner, S. Bauer, and S. Haffner Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide Blood 100 2002 334 340
15. A. Van de Stolpe, and P.T. Van der Saag Intercellular adhesion molecule-1 J Mol Med 74 1996 13 33
16. N. Mukaida, A. Harada, and K. Matsushima Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions Cytokine Growth Factor Rev 9 1998 9 23
17. K.A. Roebuck, A. Rahman, V. Lakshminarayanan, K. Janakidevi, and A.B. Malik H2O2 and TNF-α activate ICAM-1 gene transcription through distinct cisregulatory elements within the ICAM-1 promoter J Biol Chem 270 1995 18966 19874
18. C.C. Chadwick, L.J. Shaw, and R.C. Winneker TNF-alpha and 9-cis-retinoic acid synergistically induce ICAM-1 expression: evidence for interaction of retinoid receptors with NF-kappa B Exp Cell Res 239 1998 423 429
19. M.J. May, and A. Ager ICAM-1-independent lymphocyte transmigration across high endothelium: differential up-regulation by interferon gamma, tumor necrosis factor-alpha and interleukin 1 beta Eur J Immunol 22 1992 219 226
20. J.E. Pease, and I. Sabroe The role of interleukin-8 and its receptors in inflammatory lung disease: implications for therapy Am J Respir Med 1 2002 19 25
21. W.A. Boisvert, L.K. Curtiss, and R.A. Terkeltaub Interleukin-8 and its receptor CXCR2 in atherosclerosis Immunol Res 21 2000 129 137
22. S.P. Atamas, and B. White The role of chemokines in the pathogenesis of scleroderma Curr Opin Rheumatol 15 2003 772 777
23. R. Gamberale, J.R. Geffner, A. Trevani, A. Chernavsky, M. Scolnik, and G. Arrosagaray Immune complexes inhibit apoptosis of chronic lymphocytic leukaemia B cells Br J Haematol 107 1999 870 876
24. J.E. Coligan, A.M. Kruibeed, D.H. Margulies, E.M. Shevach, and W. Stroeber Morphological and biochemical assays of apoptosis Current protocols in immunology 1994 John Wiley and Sons 3.17.1 3.17.6
25. I. Nicoletti, M.C. Migliorati, C. Pagliacci, F. Grignani, and C. Ricciardi A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry J Immunol Methods 139 1991 271 279
26. L.L. Molinero, M.B. Fuertes, M.V. Girart, L. Fainboim, G.A. Rabinovich, and M.A. Costas NF-kappa B regulates expression of the MHC class I-related chain A gene in activated T lymphocytes J Immunol 173 2004 5583 5590
27. S. Harvey, R. Decker, Y. Dai, G. Schaefer, L. Tang, and L. Kramer Interactions between 2-fluoroadenine 9-beta-d-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells Clin Cancer Res 7 2001 320 330
28. A. Tamanini, R. Rolfini, E. Nicolis, P. Melotti, and G. Cabrini MAP kinases and NF-kappaB collaborate to induce ICAM-1 gene expression in the early phase of adenovirus infection Virology 307 2003 228 242
29. S. Srinivasan, D.T. Bolick, M.E. Hatley, R. Natarajan, K.B. Reilly, and M. Yeh Glucose regulates interleukin-8 production in aortic endothelial cells through activation of the p38 mitogen-activated protein kinase pathway in diabetes J Biol Chem 279 2004 31930 31936
30. N. Mukaida, S. Okamoto, Y. Ishikawa, and K. Matsushima Molecular mechanism of interleukin-8 gene expression J Leukoc Biol 56 1994 554 558
31. S. Vlahopoulos, I. Boldogh, A. Casola, and A.R. Brasier Nuclear factor-kappaB-dependent induction of interleukin-8 gene expression by tumor necrosis factor alpha: evidence for an antioxidant sensitive activating pathway distinct from nuclear translocation Blood 94 1999 1878 1889
32. V.J. Palombella, O.J. Rando, A.L. Goldberg, and T. Maniatis The ubiquitin-proteasome pathway is required for processing the NF-kB1 precursor protein and the activation of NF-kB Cell 78 1994 773 785
33. A.S. Baldwin The NF-kB and IkB proteins: new discoveries and insights Annu Rev Immunol 14 1996 649 681
34. H.M. Wu, K.H. Chi, and W.W. Lin Proteasome inhibitors stimulate activator protein-1 pathway via reactive oxygen species production FEBS Lett 526 2002 101 105
35. M.S. Hipp, C. Urbich, P. Mayer, J. Wischhusen, M. Weller, and M. Kracht Proteasome inhibition leads to NF-kappaB-independent IL-8 transactivation in human endothelial cells through induction of AP-1 Eur J Immunol 32 2002 2208 2217
36. Y. Mitsuno, H. Yoshida, S. Maeda, K. Ogura, Y. Hirata, and T. Kawabe Helicobacter pylori induced transactivation of SRE and AP-1 through the ERK signalling pathway in gastric cancer cells Gut 49 2001 18 22
37. I. Herr, and K.M. Debatin Cellular stress response and apoptosis in cancer therapy Blood 98 2001 2603 2614
38. M. Eriksson, L. Arminen, M.L. Karjalainen-Lindsberg, and S. Leppa AP-1 regulates alpha2beta1 integrin expression by ERK-dependent signals during megakaryocytic differentiation of K562 cells Exp Cell Res 304 2005 175 186
39. C.C. Chen, M.P. Chow, W.C. Huang, Y.C. Lin, and Y.J. Chang Flavonoids inhibit tumor necrosis factor-alpha-induced up-regulation of intercellular adhesion molecule-1 (ICAM-1) in respiratory epithelial cells through activator protein-1 and nuclear factor-kappaB: structure-activity relationships Mol Pharmacol 66 2004 683 693
40. M. Vitiello, M. D'Isanto, M. Galdiero, K. Raieta, A. Tortora, and P. Rotondo Interleukin-8 production by THP-1 cells stimulated by Salmonella enterica serovar Typhimurium porins is mediated by AP-1, NF-kappaB and MAPK pathways Cytokine 27 2004 15 24
41. Z. Xia, M. Dickens, J. Raingeaud, R.J. Davis, and M.E. Greenberg Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis Science 270 1995 1326 1331
42. C. Akgul, D.A. Moulding, and S.W. Edwards Molecular control of neutrophil apoptosis FEBS Lett 487 2001 318 322
43. A.A. Stone, and T.C. Chambers Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells Exp Cell Res 254 2000 110 119
44. C. Brantley-Finley, C.S. Lyle, L. Du, M.E. Goodwin, T. Hall, and D. Szwedo JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide Biochem Pharmacol 66 2003 459 469
45. D. Sampath, and W. Plunkett The role of c-Jun kinase in the apoptotic response to nucleoside analogue-induced DNA damage Cancer Res 60 2000 6408 6415
46. S.C. Maggio, R.R. Rosato, L.B. Kramer, Y. Dai, M. Rahmani, and D.S. Paik The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells Cancer Res 64 2004 2590 2600
47. J. Fang, Z. Cao, Y.C. Chen, E. Reed, and B.H. Jiang 9-beta-d- arabinofuranosyl-2-fluoroadenine inhibits expression of vascular endothelial growth factor through hypoxia-inducible factor-1 in human ovarian cancer cells Mol Pharmacol 66 2004 178 186
48. R. Ruiz-Ramos, M.E. Cebrian, and E. Garrido Benzoquinone activates the ERK/MAPK signaling pathway via ROS production in HL-60 cells Toxicology 209 2005 279 287
49. G.D. Frank, S. Eguchi, T. Yamakawa, S. Tanaka, T. Inagami, and E.D. Motley Involvement of reactive oxygen species in the activation of tyrosine kinase and extracellular signal-regulated kinase by angiotensin II Endocrinology 141 2000 3120 3126
50. F.R. Mauro, R. Foa, R. Cerretti, D. Giannarelli, S. Coluzzi, and F. Mandelli Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features Blood 95 2000 2786 2792
51. M. Churn, and V. Clough Autoimmune thrombocytopenia associated with the first cycle of fludarabine therapy in the treatment of relapsed non-Hodgkin's lymphoma Clin Oncol (R Coll Radiol) 13 2001 273 275